Αρχειοθήκη ιστολογίου

Τετάρτη 4 Απριλίου 2018

PD-L1 immuno-expression assay in thymomas: Study of 84 cases and review of literature

Publication date: Available online 4 April 2018
Source:Annals of Diagnostic Pathology
Author(s): Prerna Guleria, Nuzhat Husain, Saumya Shukla, Sunil Kumar, Rajinder Parshad, Deepali Jain
Background and aimsProgrammed death ligand 1 (PD-L1), an immune check point inhibitor, is known to be expressed in several malignancies and is being considered as a prognostic factor and a potential immunotherapeutic target. The aim of this study was to characterize PD-L1 expression in thymomas and to determine correlation with clinicopathological features and previously published studies in the literature.MethodsTissue microarrays were prepared from selected blocks of thymomas and immunohistochemistry (IHC) for PD-L1 was performed. Cases were considered as PD-L1 positive or negative depending on whether the percentage of stained thymic epithelial cells were <25 or >25%. Results were compared clinically and with previously published studies using Google and Pubmed search engines.ResultsOf 84 cases of thymoma, 69 (82.1%) revealed PD-L1 positivity in >25% cells. 94.23% of type B thymoma subtypes (B1/B2/B3) were PD-L1 positive (P < 0.001). There was no correlation of PD-L1 with age, gender, myasthenia gravis, the tumor size or stage of disease. Nine studies were available in the literature; most of which showed PD-L1 expression in higher stage and B subtype however percentage positivity varied from 53.7% to over 90%.ConclusionsPD-L1 expression is frequent in type B (B1/B2/B3) thymomas. It can be easily evaluated by IHC even on small biopsies in unresectable cases, thereby enabling improved clinical evaluation as well as prognostic stratification of patients. It will serve as a potential indicator for benefit from anti-PD-L1 antibody immunotherapy in thymomas.



from #ORL-AlexandrosSfakianakis via ola Kala on Inoreader https://ift.tt/2JlPVt5

Δεν υπάρχουν σχόλια:

Δημοσίευση σχολίου